ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 91 filers reported holding ONCOMED PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $0 | -100.0% | 15 | -99.6% | 0.00% | – |
| Q3 2018 | $8,000 | -82.6% | 3,948 | -80.6% | 0.00% | – |
| Q2 2018 | $46,000 | +12.2% | 20,302 | +55.5% | 0.00% | -100.0% |
| Q1 2018 | $41,000 | +173.3% | 13,059 | +279.2% | 0.00% | +100.0% |
| Q3 2017 | $15,000 | -34.8% | 3,444 | -51.0% | 0.00% | 0.0% |
| Q2 2017 | $23,000 | -93.3% | 7,034 | -81.2% | 0.00% | -93.3% |
| Q1 2017 | $344,000 | +158.6% | 37,436 | +116.6% | 0.02% | +87.5% |
| Q4 2016 | $133,000 | -52.8% | 17,285 | -30.0% | 0.01% | -57.9% |
| Q3 2016 | $282,000 | +623.1% | 24,677 | +674.1% | 0.02% | +533.3% |
| Q2 2016 | $39,000 | +105.3% | 3,188 | +68.6% | 0.00% | +50.0% |
| Q1 2016 | $19,000 | -91.6% | 1,891 | -81.1% | 0.00% | -88.9% |
| Q4 2015 | $225,000 | +192.2% | 10,019 | +113.9% | 0.02% | +200.0% |
| Q3 2015 | $77,000 | -43.8% | 4,683 | -23.6% | 0.01% | -45.5% |
| Q2 2015 | $137,000 | – | 6,131 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |